News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

New use of cancer therapy can halve risk of death

New use of cancer therapy can halve risk of death


News release
10 November 2006
For immediate release

MedSafe registration approval has been given for a new use of a cancer treatment for patients diagnosed with indolent non-Hodgkin’s lymphoma (NHL).

MabThera® (rituximab), a monoclonal antibody, has been approved for maintenance treatment of indolent NHL. Maintenance therapy is administered to patients after the completion of the primary therapy (commonly chemotherapy) to prevent relapse or recurrence once their cancer has gone into remission.

The submission to Medsafe by Roche Products (New Zealand) Limited incorporated Phase III clinical trial data on 465 patients worldwide, including 11 New Zealand patients. The data showed that maintenance therapy with MabThera can reduce the risk of death for relapsed indolent NHL patients by up to 48 percent1, and can extend the progression free survival time (the probability a patient will remain alive without the disease progressing or getting worse) by 60 percent (p<0.0001), which is regarded as very significant statistically in the final analysis .

Dr Peter Browett, Medical Director of the Leukaemia and Blood Foundation, says the announcement is excellent news for NHL sufferers as this is the first time the benefit of maintenance therapy in lymphoma has been clearly demonstrated.

“Maintenance treatment with MabThera offers patients the chance to gain several years of life free from disease and has been shown to prolong survival”.

“Indolent NHL is currently viewed as an incurable and recurring disease but the introduction of maintenance treatment could change it to a more manageable chronic disease, which will have huge benefits to patients.”

Dr Browett says approximately 700 New Zealanders are diagnosed with non-Hodgkin’s lymphoma each year2 and almost half of these (45 per cent)3 will be diagnosed with an indolent, slower growing form of the disease.

It is estimated that more than 150 patients with indolent non-Hodgkin’s lymphoma will relapse every year in New Zealand3, many requiring periods of hospitalisation and potentially unpleasant and life disrupting treatment with chemotherapy or radiotherapy.

Registration approval in New Zealand comes soon after European approval.

MabThera belongs to a class of pharmaceutical treatments called biological therapies. Unlike traditional chemotherapies, which are often derived from chemicals that attack growing cells directly, biological therapies work with the body’s immune system to assist it in identifying, combating and ‘killing’ cancer cells and tumours.

The treatment works with the body’s immune system to remove B cells, a type of white blood cell that can cause non-Hodgkin’s lymphoma. The body then generates new, healthy B cells to replace the ones that have been lost.

Maintenance treatment with MabThera will initially be made available as an unfunded medicine to indolent NHL patients in the private setting, although Stuart Knight, Sales and Marketing Director at Roche Products (New Zealand) Limited says an application for PHARMAC funding will be made during 2007.

He says MabThera will be beneficial as a maintenance therapy because it does not need to be used in combination with chemotherapy and is well tolerated by patients.

Ends


© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Handcrafted Form: Rare Treasures From Japan

This unique exhibition at Expressions Whirinaki represents 90 everyday objects made by contemporary Japanese artisans who employ various traditional craft techniques made in regional workshops. The works used in daily life are crafted from raw materials with techniques appropriate to bringing out the best of its medium, balancing ease of use with aesthetic appeal. More>>

Howard Davis Article: A Musical Axis - Brahms, Wagner, Sibelius

Brahms' warm and exquisitely subtle Symphony No. 3 in F major, Wagner's irrepressibly sentimental symphonic poem Siegfried Idyll, and Sibelius' chilling and immensely challenging Violin Concerto in D minor exemplify distinct stages of development in a tangled and convoluted series of skirmishes that came to define subsequent disputes about the nature of post-Romantic orchestral writing well into the following century. More>>

ALSO:

Scoop Review Of Books: A Pale Ghost Writer

Reviewed by Ruth Brassington, Richard Flanagan's new novel is about a novelist hastily ghost-writing the biography of a crook about to go to trial. The reader is kept on a cliff-edge, as the narrator tries to get blood out of his stone man. More>>

New Zealand Wars Commemoration: Witi Ihimaera's Sleeps Standing Moetū

The second of several articles to mark Rā Maumahara, remembering the New Zealand Land Wars. The first was a Q&A with Vincent O’Malley, author of The Great War for New Zealand: Waikato 1800–2000. More>>

ALSO:

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland